Navigation Links
AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy

e). The study was started in August 2005 and finalized in April 2007, and in effect demonstrates the safety and efficacy of AMT-010. All patients are now taking part in a follow-up trial, which will last for 12 months.

Efficacy

The primary endpoints of the study were either median fasting plasma triglyceride (TG) levels after administration of AMT-010 equal to or less than 10 mmol/L, or a 40% reduction in median fasting plasma TG after administration on top of a fat-free diet. For all subjects a substantial reduction of median TG levels was observed. Three patients (one from the low dose and 2 from the mid dose group) hit the primary endpoint, with TG levels below the target level of 10 mmol/L or a 40% reduction in TG levels. In two patients of the mid dose group the reduction of TG coincided with expression of active LPL in the injected muscle at 26-32 weeks after vector administration, which clearly demonstrates long-term expression of the therapeutic gene.

Safety

Furthermore, the study shows that AMT-010 was well-tolerated; there were no drug-related severe adverse events, and no dose-limiting toxicity. There was no measurable sign of local or systemic inflammation and no increase in creatinine phosphokinase concentrations, which implies that the impact on tissue function is limited and not harmful to humans.

About AMT

Amsterdam Molecular Therapeutics BV (AMT) is a gene therapy company founded by scientists of the University of Amsterdam Medical Center (AMC) in 1998. AMT focuses on the development of gene-based therapies for orphan diseases. AMT's technology allows long-term gene expression and the specific delivery of therapeutic genes to target organs or tissues. AMT has optimized and validated the production of AAV-based gene therapy vectors. The result is a unique, stable, and scalable GMP production platform. Its lead product, AMT-011, is in pre-registration trials for the first indication: treatment of comp
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:4/24/2015)... -- Hospira, Inc. (NYSE: HSP ), ... spoke about the importance of extrapolation in bringing biosimilars ... annual European Biosimilars Group conference in London ... publication of a pivotal white paper titled, "Why ... biosimilars." Speaking at the EGA conference, ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... 23, 2015 Once again, BeaconMedaes is meeting ... to patient safety. BeaconMedaes, priority is to ... disease. The next generation Zone Valve Box ... are now mounted in the assembly, allowing for ease ... ceiling tiles potentially releasing dust spores and other bacteria ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2
(Date:4/27/2015)... April 27, 2015 The ... 2015” provides comparative analysis on the therapeutic ... strengthens R&D pipelines by identifying new targets ... products. Complete report on H1 2015 pipeline ... data tables and 14 figures, spread across ...
(Date:4/27/2015)... The Radiology Business Management Association ... applied business information and intelligence, is proud to announce ... newsletter for its more than 2,000 members. , “RBMA ... news sources in that it is exclusively devoted to ... radiology. The newsletter is produced in cooperation with Thorn ...
(Date:4/27/2015)... Final Cut Pro X users ... from Pixel Film Studios. A telestrator is a device that ... moving or still video image. Telestrators are often used in ... or incoming weather patterns. , After users are done drawing,users ... frame slider to control the speed of the animation. This ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 PREVENT Life ... expanding its Texas operations with the addition of an ... life safety services to a growing customer base, Curtis ... as a new Senior Account Manager. Curtis has been ... support existing customers throughout the Houston area and beyond. ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Launched ... Amazon engineer, ZendyBeauty offered consumers a way to ... at affordable prices. Using a patent-pending Pick Your ... standard procedures like Botox®, laser hair removal and ... their staff had gaps in their schedules. This ...
Breaking Medicine News(10 mins):Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Radiology Business Management Association Launches Weekly Legislative and Policy Newsletter 2Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2Health News:PREVENT Life Safety Services Welcomes Curtis Rice as a New Senior Account Manager in Houston, TX 2Health News:ZendyBeauty Is Pleased to Announce the Expansion and Rebranding of the Company as ZendyHealth.com 2
... obesity is widely viewed as contributing to type 2 ... Hospital Boston report that two proteins activated by inflammation ... and that boosting the activity of these proteins ... mice. The research, led by Umut Ozcan, ...
... have developed a formula to predict which heart transplant patients ... their surgeries, information that could help medical teams figure out ... organs. "Donor hearts are a limited resource," says John ... Hopkins University School of Medicine and the senior author of ...
... and his group at the McCormick School of Engineering ... previously ignored mechanism in modeling how humans travel. ... professor of engineering sciences and applied mathematics, hopes to ... of disease and the spread of human-mediated bioinvasions. ...
... (Sept. 2, 2011) -- Medical students who practiced on ... scored significantly higher on their final examinations than did ... an obstetric clerkship. Results of the University of ... 2011 issue of the high-impact journal Obstetrics & ...
... Sept. 2 (HealthDay News) -- Joining a gym is the first ... better shape. But for many, joining is also the last step ... Courthouse Athletic Club in Salem, Ore. Some come once or ... said. Others don,t show up at all. "There,s an idea ...
... HealthDay Reporter , THURSDAY, Sept. 1 (HealthDay News) -- ... health problem at some point in their life, a new ... them. Mental health issues run the gamut from depression ... suffering presently do not get help, experts say. ...
Cached Medicine News:Health News:New tactic for controlling blood sugar in diabetes contradicts current view of the disease 2Health News:Researchers develop new way to predict heart transplant survival 2Health News:Researchers investigate new mechanism for predicting how diseases spread 2Health News:Simulation training in obstetric clerkship improves medical students' examination scores 2Health News:Simulation training in obstetric clerkship improves medical students' examination scores 3Health News:To Get Up and Get Moving, Joining a Gym Might Help 2Health News:Half of Americans Will Suffer From Mental Health Woes, CDC Says 2Health News:Half of Americans Will Suffer From Mental Health Woes, CDC Says 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: